Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025

Page 10 of 14

5. INmune Bio Inc (NASDAQ:INMB)

Number of Hedge Fund Holders In Q4 2024: 10

INmune Bio Inc (NASDAQ:INMB) is a biotech company that makes treatments that target the innate immune system to fight disease, with two main product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform and the Natural Killer Cell Priming Platform.

The stock is up significantly so far in 2025 as it announced plans to submit a Biologics License Application (BLA) to the FDA seeking approval of CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in pediatric patients.

This announcement followed positive results from the MissionEB study. INmune Bio also plans to submit Marketing Authorization Applications (MAAs) to the European Union and UK in 2026.

The consensus price target of $22.8 implies 190.45% upside.

INMB is up 68.09% year-to-date.

Page 10 of 14